- Home
- UTHR vs FTAI Comparison
UTHR vs FTAI Comparison
Compare UTHR & FTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- FTAI
- Stock Information
- Founded
- UTHR 1996
- FTAI 2011
- Country
- UTHR United States
- FTAI United States
- Employees
- UTHR N/A
- FTAI N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- FTAI Misc Corporate Leasing Services
- Sector
- UTHR Health Care
- FTAI Industrials
- Exchange
- UTHR Nasdaq
- FTAI Nasdaq
- Market Cap
- UTHR 13.8B
- FTAI 15.5B
- IPO Year
- UTHR 1999
- FTAI 2015
- Fundamental
- Price
- UTHR $405.02
- FTAI $171.66
- Analyst Decision
- UTHR Strong Buy
- FTAI Strong Buy
- Analyst Count
- UTHR 15
- FTAI 12
- Target Price
- UTHR $449.13
- FTAI $184.92
- AVG Volume (30 Days)
- UTHR 902.7K
- FTAI 1.2M
- Earning Date
- UTHR 10-29-2025
- FTAI 10-29-2025
- Dividend Yield
- UTHR N/A
- FTAI 0.70%
- EPS Growth
- UTHR 17.94
- FTAI N/A
- EPS
- UTHR 25.63
- FTAI 4.05
- Revenue
- UTHR $3,077,800,000.00
- FTAI $2,142,930,000.00
- Revenue This Year
- UTHR $13.89
- FTAI $44.10
- Revenue Next Year
- UTHR $5.68
- FTAI $18.24
- P/E Ratio
- UTHR $15.80
- FTAI $42.39
- Revenue Growth
- UTHR 17.62
- FTAI 55.95
- 52 Week Low
- UTHR $266.98
- FTAI $75.06
- 52 Week High
- UTHR $436.95
- FTAI $181.64
- Technical
- Relative Strength Index (RSI)
- UTHR 71.35
- FTAI 76.85
- Support Level
- UTHR $395.00
- FTAI $160.00
- Resistance Level
- UTHR $401.62
- FTAI $167.49
- Average True Range (ATR)
- UTHR 13.35
- FTAI 5.55
- MACD
- UTHR 6.12
- FTAI 1.30
- Stochastic Oscillator
- UTHR 76.31
- FTAI 96.58
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About FTAI FTAI Aviation Ltd.
FTAI Aviation Ltd is a aerospace company .It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.